Oxford Nanopore Technologies
在场
Oxford Nanopore Technologies 是一家在股票代码 ONT (GB) 下上市的公司。
高管
查看带有其 42 名主要高管的组织结构图
Oxford Nanopore Technologies 搜索最多的简介
- Gordon Sanghera, Chief Executive Officer, Executive Director
- Sarah Wild, Non Executive Director
- Kate Priestman, Non-Executive Director
高管在Oxford Nanopore Technologies变化
- Nick Keher已作为Chief Financial Officer and Director加入公司 (新闻发布的2024一月23号).
- Tim Cowper 曾任 Director, Chief Financial Officer and Head Investor Relations, Customer Services, Global IT, Business Systems & Digital, 现任 Director and Chief Operating Officer (新闻发布的2024一月23号).
- Heather Preston已作为Director加入公司 (新闻发布的2023十二月20号).
创建提醒
跟踪 Oxford Nanopore Technologies 的高管变动
生物技术
Oxford Nanopore Technologies 拥有 2,275 家竞争者，其中包括 Eurofins (卢森堡)、Lonza (瑞士) 和 Adaptive Phage Therapeutics (美国(美洲))。
Popular M&A news in 生物技术
- Histogen has filed for bankruptcy protection (公布2024四月19号).
- Bruker has announced the acquisition of NanoString Technologies (公布2024四月18号).
- Vertex Pharmaceuticals has announced the acquisition of Alpine Immune Sciences (公布2024四月16号).
生物技术 行业的其他推荐联系人
消息
Oxford Nanopore Technologies 的最新新闻稿
- Gene expression | Oxford Nanopore Technologies | Oxford Nanopore Technologies
- Subscribe to regulatory news
- The first complete sequence of a human genome
- London Calling 2021: Day 3
- Oxford Nanopore Tech Update: new Duplex method for Q30 nanopore single molecule reads, PromethION 2, and more
- London Calling 2021: Day 2
- Blog: You can’t put a label on innovation, or can you?
- London Calling 2021: Day 1
- Genomics England to evaluate Oxford Nanopore’s real-time, high-throughput DNA sequencing technology for rapid genomic analysis of cancer
- NIH to use Oxford Nanopore’s PromethION in Alzheimer’s and related dementias research
- View more press releases Close
通过电子邮件
